Growing attention around semaglutide vision loss has led to increased scrutiny of potential links between semaglutide medications and NAION. NAION is a type of ischemic optic neuropathy that occurs when blood flow to the optic nerve is reduced, potentially leading to sudden and sometimes permanent vision impairment. While this type of GLP-1 vision risk appears to be rare, patients should be aware of possible semaglutide vision side effects, particularly sudden or unexplained changes in eyesight.

Early symptoms of NAION are often sudden and painless, making them easy to overlook. Common signs associated with Ozempic NAION concerns include sudden vision loss in one eye, often noticed upon waking, blurred or dim vision, headache or periocular discomfort, loss of peripheral or side vision, a shadow, dark spot, or “curtain” effect and reduced color contrast or visual clarity. These symptoms may indicate optic nerve damage and should be evaluated immediately by a medical professional to rule out serious eye complications from semaglutide or other underlying causes.

NAION is generally not reversible. Vision loss caused by optic nerve damage is often permanent, although some individuals may experience partial improvement over time.

Because this form of ischemic optic neuropathy cannot typically be undone, early detection and management of contributing risk factors are critical. This includes monitoring for Ozempic vision loss symptoms and addressing vascular health conditions such as diabetes or hypertension.

Understanding your individual risk profile is key to minimizing potential GLP-1 vision risk and avoiding preventable complications. Certain individuals may be at higher risk for semaglutide/GLP-1 vision side effects or other complications. You should consult with a medical professional before using GLP-1 medications if you:

• Have a history of optic nerve conditions, including NAION
• Have diabetic retinopathy or pre-existing eye disease
• Have experienced prior episodes of sudden vision loss
• Have a personal or family history of medullary thyroid carcinoma
• Have Multiple Endocrine Neoplasia syndrome type 2 (or MEN 2)

Semaglutide is a generic name for Ozempic.

Ozempic is manufactured by Novo Nordisk.

Rybelsus is a daily oral tablet that contains the same medication as the weekly injectable Ozempic.

Studies show that prolonged use of Ozempic may increase the risk of several side effects, but mostly notably NAION for which there is no treatment and most commonly leads to blindness.

No, if you are diagnosed with a side effect after taking Ozempic for weight loss, you may still have a claim. 

Seek immediate medical care if you’ve experienced:

• Sudden or painless vision loss
• A shadow, blur, or obstruction in your visual field
• Rapid changes in eyesight
• Loss of peripheral vision

These may be signs of sudden vision loss causes linked to optic nerve conditions or eye complications from semaglutide.

Consider legal consultation if:

• You’ve experienced Ozempic vision loss or were diagnosed with NAION after using semaglutide
• The condition has resulted in long-term or permanent damage
• You’ve experienced financial or quality-of-life impact